• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease

September 5, 2016
Laurie Anne Walden, DVM, ELS

An antibody against nerve growth factor improved activity levels and pain scores in cats with degenerative joint disease in a pilot study recently published in the Journal of Veterinary Internal Medicine.

An antibody against nerve growth factor improved activity levels and pain scores in cats with degenerative joint disease in a pilot study recently published in the Journal of Veterinary Internal Medicine. The effect appeared to last about 6 weeks.

Nexvet Biopharma developed a felinized anti—nerve growth factor monoclonal antibody, NV-02 (frunevetmab), as a subcutaneous injectable to control osteoarthritis pain in cats. Nerve growth factor regulates the survival of neurons during development and activates pain pathways at inflammation sites in the adult. Previous studies have shown that anti—nerve growth factor antibody alleviates chronic pain in rodents, humans, and dogs.

The study included 34 pet cats with degenerative joint disease. Owners completed subjective client-specific outcome measure instruments and feline musculoskeletal pain indexes at the beginning of the study. Cats underwent physical examinations, radiography, and blood and urine tests. For the first 2 weeks, cats wore collar-mounted accelerometers to measure their baseline activity levels.

Advertisement

On day 14, each cat received a single subcutaneous injection of 0.4 mg/kg NV-02, 0.8 mg/kg NV-02, or sterile saline. Over the next 11 weeks, the investigators collected accelerometer data and the owners completed additional outcome measure assessments and pain indexes. At the end of the study, investigators repeated the physical examinations and laboratory tests. Clients completed final assessments of their cats and indicated whether they thought their cats had received NV-02 or placebo.

Activity levels measured by accelerometry were significantly higher 2 to 6 weeks after injection in cats receiving NV-02 than in cats receiving placebo. The differences between the 2 doses of NV-02 were not significant. The increase in activity during the first 3 weeks after NV-02 injection was similar to or higher than that measured after daily meloxicam treatment in an earlier study, write the authors.

Owner-assessed outcome scores significantly improved for all cats in the study, including those receiving placebo, at nearly every time point. Scores were significantly higher 3 weeks after injection (but not at other time points) in cats receiving NV-02 than in those receiving placebo. Most owners (83%) of cats receiving NV-02 correctly guessed that their cats had received treatment; only 45% correctly guessed that their cats had received placebo.

By the end of the study, mean total protein and serum globulin concentrations were significantly higher in cats receiving NV-02 than in those receiving placebo. The investigators found no association between adverse events (which were mild in 6 cats and serious in 1) and NV-02 administration.

The authors concluded that the results indicated a positive treatment effect despite the large placebo response. “We believe that the potential impact in veterinary medicine of an injection lasting approximately 6 weeks for the control of long-term pain in the cat is very positive and clinically relevant,” they write.

Nexvet Biopharma supported the study. The lead author received funding from the National Institutes of Health. One of the authors is a paid consultant for Nexvet, and another is a Nexvet employee.

Dr. Laurie Anne Walden received her doctorate in veterinary medicine from North Carolina State University. After an internship in small animal medicine and surgery at Auburn University, she returned to North Carolina, where she has been in small animal primary care practice for over 20 years. Dr. Walden is also a board-certified editor in the life sciences and owner of Walden Medical Writing, LLC.

Related Content:

Pain Management
FHO vs total hip replacement: separating fact from fiction
FHO vs total hip replacement: separating fact from fiction
Dog owners are not getting proactive OA information from their veterinarians
Dog owners are not getting proactive OA information from their veterinarians
The vital value of treating patient pain
The vital value of treating patient pain

Advertisement

Latest News

New technology and products for veterinary genealogy

Reduce your veterinary teams’ stress with financial wellness

Cuban crocodiles receive surgery to extract foreign items

Purina Pro Plan Veterinary Diets joins forces with AVMF

View More Latest News
Advertisement